BD (Becton, Dickinson and Company) is set to participate in CPhI Barcelona 2023. This event will take place from 24 to 26 October 2023 in Barcelona, Spain, and will primarily focus on the latest advancements in pharmaceutical packaging and drug delivery systems.
BD plans to showcase its extensive range of products and solutions designed to meet the evolving needs of the pharmaceutical and biotechnology sectors.
At the conference, BD will present a diverse portfolio of products, services and integrated solutions. These offerings are tailored to assist pharmaceutical and biotech companies engaged in developing combination products.
BD’s experts will be available at the event to engage in discussions about the future of drug delivery.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPrefillable syringes for vaccination needs
BD will introduce its pre-fillable syringe (PFS) portfolio, including the BD Effivax Glass Prefillable Syringe. This next-generation glass pre-fillable syringe has been developed in collaboration with leading pharmaceutical companies to meet the complex requirements of vaccine manufacturing.
See Also:
It sets new performance standards with enhanced specifications for processability, aesthetics and integrity.
BD is actively involved in supporting the delivery of medications addressing chronic diseases such as diabetes, obesity, oncology and autoimmune disorders.
Their advanced drug delivery systems include self-injection systems suitable for a wide range of volumes and viscosities.
Notable products include the BD Libertas Wearable Injector, designed for the subcutaneous delivery of large-volume, high-viscosity biologics in a single-use, disposable “ready-to-use” system and the BD Evolve On-body Injector, a programmable on-body injector allowing subcutaneous administration of up to three millilitres of medication over three days of wear.
Support for co-packing and co-delivery
BD also offers solutions for customers seeking to co-pack or co-deliver administration devices with their drugs. These services are often utilised to ensure proper administration, serve end-users, or manage drug administration materials, particularly in clinical trials.
BD’s devices cover a broad range of applications, including ophthalmic drug reconstitution, cell and gene therapies, home use of chronic drugs and vaccination campaigns.
A wide range of services will be presented, including BD Pharmaceutical Services and Solutions and ZebraSci. combination product services. These services aim to assist pharmaceutical companies in achieving their goals from the development stage to product launch.
BD will also feature an “Innovation Corner” where they will unveil new product innovations and concepts. These innovations focus on product traceability, quality, digital connectivity of injection data and a flexible large-volume solution platform to cater to patients’ medication delivery needs.
